Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.33 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.33 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10357844 | 1.00 | NR1I2 (0.46) | NR1I2SLC2A1LMNADNM1ALDH1A1 | |
| SCHEMBL10358358 | 0.98 | NR1I2 (0.45) | NR1I2SLC2A1LMNADNM1ALDH1A1 | |
| SCHEMBL983798 | 0.98 | NR1I2 (0.44) | NR1I2SLC2A1LMNAALDH1A1CSNK1E | |
| SCHEMBL6850756 | 0.96 | NR1I2 (0.44) | NR1I2SLC2A1LMNADNM1ALDH1A1 | |
| SCHEMBL5480284 | 0.96 | NR1I2 (0.44) | NR1I2SLC2A1LMNADNM1ALDH1A1 | |
| SCHEMBL10358926 | 0.96 | NR1I2 (0.42) | NR1I2SLC2A1LMNADNM1ALDH1A1 | |
| SCHEMBL8859009 | 0.94 | NR1I2 (0.41) | NR1I2SLC2A1OPRM1 | |
| SCHEMBL28140502 | 0.92 | NR1I2 (0.55) | NR1I2SLC2A1LMNADNM1ALDH1A1 | |
| SCHEMBL6162603 | 0.92 | NR1I2 (0.55) | NR1I2SLC2A1LMNADNM1ALDH1A1 | |
| SCHEMBL817130 | 0.92 | NR1I2 (0.38) | NR1I2SLC2A1DNM1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275406-B1 | PROCESS FOR PRODUCING ISOCYANATE | ASAHI CHEMICAL IND (JP) | 2018-11-28 | — | — | EP | disclosed |
| US-9233918-B2 | Isocyanate production process | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-01-12 | — | — | US | disclosed |
| CN-102026965-B | Method for producing isocyanate | ASAHI KASEI CHEMICALS CORP | 2014-02-26 | — | — | CN | disclosed |
| US-20110092731-A1 | ISOCYANATE PRODUCTION PROCESS | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| EP-2275406-A1 | PROCESS FOR PRODUCING ISOCYANATE | Asahi Kasei Chemicals Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092731-A1 | ISOCYANATE PRODUCTION PROCESS | CPS1, PHGDH, APEH | NR1I2 4608/4885SLC2A1 3368/4885LMNA 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.